Current and Emerging Therapies for the Prevention and Treatment of Osteoporosis

Current and Emerging Therapies for the Prevention and Treatment of Osteoporosis

Faculty Presenter

Cy Fixen, PharmD, BCACP
Assistant Professor
Department of Clinical Pharmacy
University of Colorado Anschutz Medical Campus
University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences

Clinical Pharmacy Specialist
University of Colorado Health
Aurora, Colorado
 
Program Description
Several assessment tools can be used to measure patient risk for osteoporosis and for osteoporosis-related fractures. Without confirmed diagnosis of osteoporosis, patients cannot receive effective pharmacologic treatment and can experience increased risk of fracture. As pharmacists are in frequent contact with patients, they are ideally positioned to review patients’ medical histories, medication list, and other factors that may increase risk for osteoporosis. They can also promote use of nonpharmacologic agents, such as calcium and vitamin D supplements, to ensure optimal bone health as part of osteoporosis prevention. Prior to initiating pharmacologic therapy, consideration must be given to the patient’s risk and fracture history, as well as limitations to administration and patient tolerance of specific medications. Although bisphosphonates are typically first-line therapies for postmenopausal osteoporosis, in 2020, the AACE/ACE guidelines were updated to include the recently approved medications for osteoporosis treatment and management as well as new recommendations for use of assessment tools to evaluate osteoporosis and fracture risk. This is the second module in the 4-part curriculum series and will review clinical trial data for new and emerging agents and their recommended use as incorporated in the updated 2020 AACE/ACE guidelines.

Target Audience: Specialty pharmacists
Type of Activity: Application
Release date: March 31, 2021
Expiration date: March 31, 2022
Time to complete activity: 1.0 hour
Fee: Free

Educational Objectives
At the completion of this activity, participants will be able to:

• Optimize nonpharmacologic recommendations for the prevention and treatment of osteoporosis
• Compare current traditional treatments for osteoporosis in terms of mechanism of action, efficacy, safety, and place in therapy
• Determine the role of new and emerging therapies, such as abaloparatide and romosozumab, in osteoporosis treatment, including mechanism of action, efficacy, safety, and place in therapy

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-21-012-H01-P. The activity is available for CE credit through March 31, 2022.


Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
 

---

Disclosures

Cy Fixen, PharmD, BCACP, has no relevant financial relationships with commercial interests to disclose.

Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Michelle Carlson, PharmD; Brianna Schauer, MBA, PMP; Kelly McCormick; Susan Pordon; and Brianna Winters have no relevant financial relationships with commercial interests to disclose.

An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms